A systematic review and meta-analysis indicate that neoadjuvant chemotherapy (nCTX) does not offer survival benefits for esophagogastric signet ring cell carcinoma (SRCC) patients. The meta-analysis, which included 3,653 patients from 10 studies, revealed that SRCC patients treated with nCTX followed by surgery have worse survival outcomes compared to those treated with surgery alone. Additionally, SRCC patients exhibit lower histopathological response rates to nCTX compared to non-SRCC patients. These findings highlight the need for further high-quality research to determine the most effective treatment strategies for SRCC. #GastricCancer #NeoadjuvantChemotherapy #OncologyResearch #SurgicalOncology
You are here: Home / Latest Updates / Esophagus Cancer Updates / Neoadjuvant Chemotherapy Fails to Improve Survival in Esophagogastric Signet Ring Cell Carcinoma: Meta-Analysis Reveals Critical Insights
Leave a Reply